Does Rallies track congressional trades in MRK?

Yes. Rallies tracks politician and congressional stock disclosures for MRK, including reported purchases, sales, dates, owners, and trade amounts when available.

Is MRK research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MRK. It does not provide personalized investment advice.

MRK (Merck) Stock Analysis - Politician Trades

Merck (MRK) is a publicly traded Healthcare sector company. As of May 20, 2026, MRK trades at $114.00 with a market cap of $278.00B and a P/E ratio of 31.77. MRK moved -1.07% today. Year to date, MRK is +5.17%; over the trailing twelve months it is +44.93%. Its 52-week range spans $73.31 to $125.14. Analyst consensus is buy with an average price target of $135.61. Rallies surfaces MRK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded MRK stock?

Recent politician trading activity in MRK includes disclosures from Josh Gottheimer, Michael McCaul, Julie Johnson, Julie Johnson, and Val Hoyle. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

MRK Key Metrics

Key financial metrics for MRK
Metric	Value
Price	$114.00
Market Cap	$278.00B
P/E Ratio	31.77
EPS	$3.57
Dividend Yield	0.85%
52-Week High	$125.14
52-Week Low	$73.31
Volume	5.25M
Avg Volume	0
Revenue (TTM)	$65.77B
Net Income	$8.93B
Gross Margin	73.91%

Congressional Trades in MRK

Josh Gottheimer purchase MRK on Feb 4, 2026 (amount: $15.00K) for Joint.
Michael McCaul sale MRK on Jan 13, 2026 (amount: $50.00K) for Spouse.
Julie Johnson sale MRK on Dec 18, 2025 (amount: $15.00K) for Joint.
Julie Johnson sale MRK on Nov 13, 2025 (amount: $15.00K) for Joint.
Val Hoyle sale MRK on Sep 23, 2025 (amount: $15.00K) for Spouse.

Latest MRK News

Merck’s 2024 Adult Pneumonia Vaccine Faces Intensified Competition from Pfizer’s 25-Strain Pediatric Shot — May 20, 2026
Merck Faces Product Liability Trial Over $8.9B Gardasil Sales Peak — May 8, 2026
Merck Animal Health Taps Salesforce Agentforce Life Sciences to Optimize Veterinary Support — May 6, 2026
Merck Finalizes $53-Per-Share Terns Acquisition, Gains FDA-Backed CML Candidate — May 6, 2026
Merck Logs Fourth Straight Beat on KEYTRUDA Growth, Secures Terns Acquisition — May 5, 2026

Recent MRK Insider Trades

Guindo Chirfi sold 10.00K (~$1.21M) on Feb 12, 2026.
Li Dean Y sold 10.23K (~$1.20M) on Feb 10, 2026.
Guindo Chirfi sold 10.00K (~$1.18M) on Feb 9, 2026.

MRK Analyst Consensus

20 analysts cover MRK: 0 strong buy, 13 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $135.61.

Common questions about MRK

Which politicians traded MRK stock?: Recent politician trading activity in MRK includes disclosures from Josh Gottheimer, Michael McCaul, Julie Johnson, Julie Johnson, and Val Hoyle. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in MRK?: Yes. Rallies tracks politician and congressional stock disclosures for MRK, including reported purchases, sales, dates, owners, and trade amounts when available.
Is MRK research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MRK. It does not provide personalized investment advice.